A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma.
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Cediranib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 08 Jun 2011 Planned end date changed from Jun 2009 to Dec 2011 as reported by ClinicalTrials.gov.
- 25 Nov 2008 Planned end date changed from 1 Apr 2006 to 1 Jun 2009.
- 19 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov